Impact of CYP2C19 genotype on escitalopram exposure and establishment of a dose algorithm for genotype-based individualization of escitalopram therapy

被引：0
|
作者：
Jukic, M. [1 ]
Molden, E. [2 ]
Ingelman-Sundberg, M. [1 ]
机构：
[1] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden
[2] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2017年 / 27卷
关键词：
D O I：
10.1016/S0924-977X(17)31537-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.2.f.017
引用
收藏
页码：S856 / S856
页数：1
相关论文
共 50 条
  • [1] Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure
    Jin, Yuyan
    Pollock, Bruce G.
    Frank, Ellen
    Cassano, Giovanni B.
    Rucci, Paola
    Mueller, Daniel J.
    Kennedy, James L.
    Forgione, Rocco Nicola
    Kirshner, Margaret
    Kepple, Gail
    Fagiolini, Andrea
    Kupfer, David J.
    Bies, Robert R.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (01): : 62 - 72
  • [2] Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients
    Jukic, Marin M.
    Haslemo, Tore
    Molden, Espen
    Ingelman-Sundberg, Magnus
    AMERICAN JOURNAL OF PSYCHIATRY, 2018, 175 (05): : 463 - 470
  • [3] Impact of CYP2C19 and CYP2D6 Genotype on Escitalopram, Risperidone, and Aripiprazole Treatment
    Jukic, Marin
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 24 - 25
  • [4] CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP
    Huezo-Diaz, Patricia
    Perroud, Nader
    Spencer, Edgar P.
    Smith, Rebecca
    Sim, Sarah
    Virding, Susanne
    Uher, Rudolf
    Gunasinghe, Cerisse
    Gray, Jo
    Campbell, Desmond
    Hauser, Joanna
    Maier, Wolfgang
    Marusic, Andrej
    Rietschel, Marcella
    Perez, Jorge
    Giovannini, Caterina
    Mors, Ole
    Mendlewicz, Julien
    McGuffin, Peter
    Farmer, Anne E.
    Ingelman-Sundberg, Magnus
    Craig, Ian W.
    Aitchison, Katherine J.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (03) : 398 - 407
  • [5] The Impact of Adherence and CYP2C19 Phenotype on Escitalopram Exposure in Adolescents
    Baumel, W. Thomas
    Poweleit, Ethan A.
    Neptune, Zoe
    Schroeder, Heidi K.
    Ramsey, Laura B.
    Mills, Jeffrey
    Strawn, Jeffrey R.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2024, 34 (01) : 67 - 69
  • [6] Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups
    Waade, Ragnhild Birkeland
    Hermann, Monica
    Moe, Hanne Lewis
    Molden, Espen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (08) : 933 - 940
  • [7] Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups
    Ragnhild Birkeland Waade
    Monica Hermann
    Hanne Lewis Moe
    Espen Molden
    European Journal of Clinical Pharmacology, 2014, 70 : 933 - 940
  • [8] Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients
    Braten, Line S.
    Haslemo, Tore
    Jukic, Marin M.
    Ingelman-Sundberg, Magnus
    Molden, Espen
    Kringen, Marianne K.
    NEUROPSYCHOPHARMACOLOGY, 2020, 45 (03) : 570 - 576
  • [9] Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients
    Line S. Bråten
    Tore Haslemo
    Marin M. Jukic
    Magnus Ingelman-Sundberg
    Espen Molden
    Marianne K. Kringen
    Neuropsychopharmacology, 2020, 45 : 570 - 576
  • [10] Dose of proton pump inhibitors and the CYP2C19 genotype
    Bertilsson, L
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2004, 95 (01) : 1 - 1
12345